Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis
A. Egan (Rochester, United States of America), M. Ali (Rochester, United States of America), G. Shaughnessy (Rochester, United States of America), H. Dasari (Montreal, Canada), V. Van Keulen (Rochester, United States of America), T. Peikert (Rochester, United States of America), E. Carmona Porquera (Rochester, United States of America)
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Egan (Rochester, United States of America), M. Ali (Rochester, United States of America), G. Shaughnessy (Rochester, United States of America), H. Dasari (Montreal, Canada), V. Van Keulen (Rochester, United States of America), T. Peikert (Rochester, United States of America), E. Carmona Porquera (Rochester, United States of America). Antifibrotics modulate B lymphocyte activation resulting in a decrease of the profibrotic milieu in patients with pulmonary fibrosis. 1290
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: